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A B S T R A C T
Purpose: Currently around 30% of all newly developed seizures are diagnosed in persons older than 65
years. Five to 17% of nursing home-residents take antiepileptic drugs. The aim of our study was to
analyze the type and frequency of prescribed antiepileptic drugs, as well as their indication, co-
morbidities and co-medications in institutionalized elderly in Austria.
Methods: This was a retrospective, cross-sectional study, which included all residents of the seven public
nursing homes in Innsbruck, Austria. The data of 828 probands were extracted from the charts at site and
maintained anonymously. The data collection was followed by descriptive statistics.
Key ﬁndings: 70 (8.5%; 26 M/44 F) of the 828 (192 M/636 F) residents took at least one antiepileptic
medication. In 51.5% the reason for the prescription were epileptic seizures – yielding a minimum
prevalence of 4.5%. The most often used antiepileptic drugs were gabapentin (37%), levetiracetam (24%)
and valproate (18.5%). The three most common co-morbidities were arterial hypertension (49%),
ischemic stroke (36%) and other cerebrovascular diseases (29%). Six to nine co-medications were
prescribed in 41%, 26% had more than 10 additional drugs and 91% were treated with proconvulsive co-
medications (64/70, median 2, range 0–6).
Signiﬁcance: Austrian nursing home residents receive more frequently newer antiepileptic drugs
compared to other countries, but co-prescription of proconvulsive drugs is common.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Compared with all other age groups persons over 75 years have
the highest incidence of acute symptomatic seizures, epilepsy and
status epilepticus.1 For the year 2020 it is expected that 50% of all
newly developed seizures will be diagnosed in patients over 65
years.2,3 In contrast to the general population nursing home
residents have even a much higher prevalence for epilepsy: 1
versus 5–6%.4–6 Antiepileptic drug (AED) use, however, varies in
the different countries: AEDs are taken in 10.5–11% of US-nursing
home-residents,7 in 4% of Italian,8 in 5% of German9, in 9% of
Swedish10 and in 17% of Irish institutionalized elderly.11 The ILAE
Guidelines recommend lamotrigine and gabapentin as the AEDs of
choice in the therapy of elderly people. Alternatively, levetirace-
tam is considered by many experts in the ﬁeld as appropriate drug
in the eldery.12 Nevertheless, phenytoin is still the most frequently
used drug in the US.7 And in German (37%),9 Swedish (32%)10 and* Corresponding author at: Department of Neurology, Christian Doppler Klinik,
Paracelsus Medical University Ignaz Harrer Strasse 79, A-5020 Salzburg, Austria.
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http://dx.doi.org/10.1016/j.seizure.2012.09.012Irish nursing homes (45%)11 it is carbamazepine. The aim of our
study is to assess the type and frequency of prescribed AEDs in
Austrian nursing homes, as well as their indication, co-morbidities
and co-medications.
2. Methods
2.1. Study design
This was a retrospective, cross-sectional study, which included
all residents of the seven public nursing homes in the district of
Innsbruck (Tyrol, Austria). The data acquisition was carried out
between 23rd March 2010 and 7th April 2010 by D.P. Huber,
always accompanied by R. Griener, the Quality Manager of
Innsbruck’s social services who ensured data security and
protection of anonymity. Following data were extracted from
the patient charts at site: name of the residential home and
number of its inhabitants, date of birth and gender of the nursing
home resident, specialization of the physician in charge, the
seizure semiology, the date of ﬁrst prescription, the indication and
the dose of AEDs, the co-morbidities and co-medications. The
informed consent was waived by the Ethics Commission of the
Medical University of Innsbruck.vier Ltd. All rights reserved.
Fig. 1. Number of co-medications prescribed next to AED in Austrian nursing home
residents.
Fig. 2. Initial AED treatment of nursing home residents in Innsbruck, Austria.
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The data were entered directly at site into the prepared data
sheet of program SPSS version 18.0 and the descriptive analysis
was carried out with SPSS 18.0. Percentages, the mean and median
with standard deviations were used to summarize baseline
information for all variables.
3. Results
At least one AED was used by 8.5% (70/828) of the
participating nursing home residents. The prevalence of patients
using AEDs in nursing home-residents was 4.5% (36/828).
Demographic data and age distribution are displayed in Table
1. Age at diagnosis was noted in the charts only in 36% (25/70):
84% (21/25) were older than 60 years at the time of their ﬁrst
seizure. Half of the patients had at least ﬁve to ten co-morbidities
(median 6, range 2–10). The two most common diseases were
arterial hypertension (49%, 34/70) and ischemic stroke (36%, 25/
70); others were peripheral arterial occlusive disease, carotid
stenosis and deep leg vein thrombosis (29%, 20/70) (see Table 2).
The substance class, the number and distribution, as well as the
proconvulsant potential of co-medications, prescribed next to
AED, are detailed in Fig. 1. In total, patients had median eight
(range 0–16) co-medications and 91% of them took next to the
AED at least one proconvulsive drug (64/70) – with a median of
two and a range of zero to six.
The three most commonly used AEDs were gabapentin (37%,
26/70), levetiracetam (24%, 17/70) and valproate (19%, 13/70) (see
Fig. 2). Median dose of gabapentin was 700 mg (range 100–
2400 mg), of levetiracetam 2000 mg (range 1000–3000 mg), of
valproate 850 mg (range 300–2000 mg), of phenytoin 300 mg
(range 200–900 mg), of carbamazepine 400 mg, of topiramate
200 mg, of primidone 375 mg and of pregabalin 225 mg (range
225–300 mg). Most patients (62%, 43/70) used one AED and nine
used two AEDs (13%, 9/70).
Indication for AED use was ascertained in 61% (43/70). Epilepsy
or epileptic seizures were the most common reason: 52% of all
participating residents got the AED because of their epilepsy (36/
70). Other indications were neuropathic pain (4%, 3/70), manic-
depressives disorders (3%, 2/70), essential tremor (1%, 1/70) and
restless legs syndrome (1%, 1/70). In 39% the indication could not
been identiﬁed. Of the 36 patients, which used AEDs because of
epilepsy, the type of epileptic seizure was ascertained by chart
entry in 64% (23/70). 22% had tonic–clonic seizures, 22% had
secondary generalized, 11% complex focal and 8% simple focal
seizures.Table 1
Demographic information on the study population.
Nursing home 
1 2 3 4 
Inhabitants 107 156 96 60 
Women, n (%) 83 (78) 123 (79) 67 (70) 45 (75
Used AED 8 12 9 6 
Sex (M/F) 3/5 3/9 3/6 3/3 
Age at diagnosis
15 a 0 0 0 0 
16–59 a 1 0 0 1 
60 a 2 5 0 2 
Unknown 5 7 9 3 
Used ﬁrst AED 2GBP, 2LEV, 1VPA,
1CBZ, 1PHT, 1PGB
6GBP 4LEV
2VPA
5GBP 1PHT
1PGB 1PRM 1TPM
2GBP, 
1LEV, 1
Abbreviations: M/F = men/women, a = years, AED = antiepileptic drug, CBZ = carbamaz
PRM = primidone, TPM = topiramate, VPA = valproic acid.4. Discussion
4.1. Main ﬁndings
8.5% of all nursing home-residents in Innsbruck took at least
one AED. In 51% the indication was Epilepsy, implying a prevalence
of 4.5%. Thus, our ﬁndings are in line with those from Swedish and
US institutions, where the prevalence of AED use is between 9 and
11%,7,10 but they are divergent to other European studies:
compared to German and Italian nursing homes the use of AEDs
in Austrian institutions is higher (4–5% versus 8.5%),8,9 compared
to Irish residents the use is lower (17% versus 8.5%).11 The
divergence may be caused by differences in data sources, the
assessment of AED use and the more recent dataset, at which time
epilepsy in the elderly and newer AEDs, such as gabapentin andTotal
5 6 7
189 126 94 828
) 154 (81) 96 (76) 68 (72) 636 (77)
16 11 8 70
3/13 7/4 4/4 26/44
0 1 0 1
0 1 0 3
5 6 1 21
11 3 7 45
2VPA,
PHT
5VPA 4GBP 3LEV
2CBZ 1PHT 1PGB
4LEV 3GBP
2VPA 2PHT
4GBP 3LEV,
1VPA
26GBP 17LEV
13VPA 6PHT 3CBZ
3PGB 1PRM 1TPM
epine, GBP = gabapentin, LEV = levetiracetam, PHT = phenytoin, PGB = pregabalin,
Table 2
The most commonly co-morbidities of Austrian nursing home residents with AED
use.
Co-morbidity Prevalence
Arterial hypertension 49% (34/70)
Ischemic stroke 36% (25/70)
Other angiopathies 29% (20/70)
Coronary heart disease 26% (18/70)
Osteoporosis 24% (17/70)
Diabetes mellitus 19% (13/70)
Atrial ﬁbrillation 19% (13/70)
Depression and/or bipolar affective disorder 17% (12/70)
Dementia 14% (10/70)
Brain hemorrhage 9% (6/70)
Head injury 7% (5/70)
Thyroid disorder 7% (5/70)
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shows that newer generation AEDs were used most frequently:
80% of the residents were treated with gabapentin (37%),
levetiracetam (24%), or valproate (19%), only 9% with phenytoin
and no one with phenobarbital. Compared to that, in USA
phenytoin was the most frequently prescribed AED with 57% of
all nursing home residents,13 despite its high potential of drug
interactions, guideline14 and expert opinion recommendations.15
Next to the more recent dataset, this could be explained by the fact,
that in Austria most prescriptions in newly diagnosed patients
with seizures were performed by neurologists and rarely by other
specialities. Thus, in Austria 52% took the AED because of epilepsy
(36/70), in Germany 63% and in US 58%7 to 80%.16 The second most
frequent situation was that the cause for AED prescription could
not be ascertained – in Germany in 30%, in Austria in 37%. So maybe
even many more residents were treated with an AED because of
epilepsy. Other diseases, like neuropathic pain, manic-depressives
disorders, essential tremor or restless legs-syndrome seem to play
a minor role: 11.5% of AED-prescriptions for Austrian residents and
13% of AED-prescriptions for US residents were based on one of
them.17 Generally spoken, seizures seem to pose the most frequent
indication for a therapy with an AED in nursing homes.Table 3
Used co-medications next to AEDs among nursing home residents in Innsbruck,
Austria.
Co-medication Incidence Proconvulsivity
Azole derivate 64% (45/70) No
Bezodiazepine derivative +
benzodiazepine analog
49% (34/70) No
56% (39/70) No
Antidepressant 44% (31/70) Yes
Atypical neuroleptic + old
neuroleptic
43% (30/70) Yes
47% (33/70) No
Diuretic + in a ﬁxed combination
with antihypertensive
46% (32/70) No
60% (42/70) In combination with
b-blocker yes
Non-opioid-pain killer + opioid 29% (20/70) No
53% (37/70) Yes
ACE-inhibitor 36% (25/70) No
b-Blocker 14% (10/70) Yes
Calcium channel blocker 13% (9/70) No
Nitrate derivate 7% (5/70) No
Angiotensin 1-antagonist 3% (2/70) No
Antihypertensiva in total 73% (51/70) Partially
Thrombo-ASS 31% (22/70) No
Clopidogrel 14% (10/70) No
Coumarin 7% (5/70) No
Heparin 4% (3/70) No
Laxative 23% (16/70) NoFurther, all of the Austrian residents had at least two co-
morbidities: 50% had a maximum of ﬁve co-morbidities and 50% had
six to ten. The three most common co-morbidities were arterial
hypertension (49%), ischemic stroke (36%) and other cerebrovascu-
lar disorders (29%). These ﬁndings conﬁrmed the study of Huying
et al., who reported that German nursing home residents had
cerebrovascular diseases in 56% and dementia, intracerebral
hematoma and other neurological diseases in 15%.9 On the contrary,
Austrian residents took twice as much co-medications as German or
US residents, where in average ﬁve medications in addition to the
AEDs were prescribed. Indeed, residents in Innsbruck received in
average nine co-medications (see Table 3). In total 91% were treated
with at least one proconvulsive drug (64/70): 77% got one to three,
14% four to six and only 9% none proconvulsive co-medication.
Compared to the study of Shorvon et al. where 11% of 294 patients
with epilepsy followed in general practice were treated with
proconvulsant co-medications, this is a concerning ﬁgure. Reasons
for this striking difference could be ﬁrst, the younger study
population in the study of Shorvon et al. with less co-medications
and co-morbidities. Second, the fact that our study included just
nursing home-residents in contrast to the community-dwelling
patients in the study of Shorvon et al. and third, the different
classiﬁcation of proconvulsant and non-proconvulsant medications
– we used the classiﬁcation of proconvulsant drugs according to a
previous publication by Stephen and Brodie,18which classiﬁed more
drugs as proconvulsant than the National General Practice of
Epilepsy Study.19
Furthermore, our results allow an indirect conclusion on the
prevalence of seizures in institutionalized elderly Austrians: 4.5%
of all residents had documented epilepsy in their medical history
(36/828). By comparison, Huying et al. showed that 3% of the
German residents had epilepsy (18/565)9 and according to three
US studies between 6.5% and 9% of the US residents suffered from
seizures (65/996,16 42/572,20 and 885/1018613). Summarized,
these results suggest a higher prevalence of epilepsy in nursing
home-residents – most likely explained by a selection bias of those
people, who need more care and attention, and probably also have
more diseases including brain diseases, which lead to a higher
seizure prevalence compared to the standard population.2,21
4.2. Limitations
First, it is a retrospective study implicating a limited statement
of the cause and outcome of seizures and therefore, prevalence and
incidence rates can only be estimated. Second, it should be noted
that the study evaluated only urban nursing homes, all situated in
proximity to the Medical University of Innsbruck with direct access
to medical specialized care and a specialized epilepsy outpatient
clinic, as well as neurological emergency unit. On the one hand this
can explain the high use of newer AEDs. And on the other hand our
results may not be representative for the nursing home residents in
Austrian rural areas. Third, the study was cross-sectional, which is
problematic because variation of AED use may be higher over a
longer time period. Forth, AED data were completely extracted
from patient records. Therefore, it was not possible to ascertain
more precise data on the indication for AED prescription, the
duration of treatment and the seizure type in all patients. In
general, however, these results show a high AED use in Austrian
nursing homes because of seizures and show that AEDs are among
the most commonly used class of neuropsychiatric medications in
Austrian nursing homes.
5. Conclusions
Austrian nursing home residents are mainly treated with newer
AEDs, like gabapentin and levetiracetam. Furthermore, the results
D.P. Huber et al. / Seizure 22 (2013) 24–27 27allow a crude estimate on prevalence of epileptic seizures in
nursing home-residents: 4.5% of the residents had documented
epilepsy in their medical history (36/828).
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